Liver Resection for Non-colorectal Non-neuroendocrine Metastases: Where Do We Stand Today Compared to Colorectal Cancer?

Schiergens, Tobias S.; Lüning, Juliane; Renz, Bernhard W.; Thomas, Michael; Pratschke, Sebastian; Feng, Hao; Lee, Serene M. L.; Engel, Jutta; Rentsch, Markus; Guba, Markus; Werner, Jens; Thasler, Wolfgang E.

doi:10.1007/s11605-016-3115-1

Cited by 33 publications

(44 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure depicts the flow diagram of article selection, according to the PRISMA statement. Thirteen articles were finally included, with a total of 378 patients. None of the retrieved studies were randomized and all of them were retrospective observational cohort reports.…”

Section: Resultsmentioning

confidence: 99%

Surgical treatment of liver metastases from kidney cancer: a systematic review

Pinotti

Montuori

Giani

et al. 2019

ANZ Journal of Surgery

View full text Add to dashboard Cite

Background: Liver metastases are present in 20.3% of metastatic kidney cancers. The aim of this literature review was to assess the efficacy of surgical treatment for hepatic metastasis from kidney cancer. Methods: An extended web search of the literature was independently performed in March 2018 by two authors according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. Results: Through electronic searches, we identified 935 potentially relevant citations. Thirteen articles were finally included in the systematic review. Median survival after resection ranged from 15 to 142 months while the 1-, 3-and 5-year overall survival ranged from 69% to 100%, 26% to 83.3% and 0% to 62%, respectively. Median disease-free survival ranged from 7.2 to 27 months. Conclusion: Surgical treatment of hepatic metastases is performed in approximately 1% of patients with liver metastases and in select patients may be potentially curative. Surgical resection of liver metastases from kidney cancer represents a valid option for selected patients with metastatic renal cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Surgical treatment of liver metastases from kidney cancer: a systematic review

Pinotti

Montuori

Giani

et al. 2019

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…In liver metastases (L‐Mets), surgical indications are consistent with the oncological features of the original tumor,92 but this applies mostly to colorectal cancer. In general, partial resection is the standard surgical procedure for metastatic liver cancer because curative treatment is achieved by performing minimized liver resection with margin 93.…”

Section: Indications and Oncological Outcomesmentioning

confidence: 99%

Evolution and revolution of laparoscopic liver resection in Japan

Kaneko

Otsuka

Kubota

et al. 2017

Annals of Gastroent Surgery

View full text Add to dashboard Cite

Due to important technological developments and improved endoscopic techniques, laparoscopic liver resection (LLR) is now considered the approach of choice and is increasingly performed worldwide. Recent systematic reviews and meta‐analyses of observational data reported that LLR was associated with less bleeding, fewer complications, and no oncological disadvantage; however, no prospective randomized trials have been conducted. LLR will continue to evolve as a surgical approach that improves patient's quality of life. LLR will not totally supplant open liver surgery, and major LLR remains to be technically challenging procedure. The success of LLR depends on individual learning curves and adherence to surgical indications. A recent study proposed a scoring system for stepwise application of LLR, which was based on experience at high‐volume Japanese centers. A cluster of deaths after major LLR was sensationally reported by the Japanese media in 2014. In response, the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery conducted emergency data collection on operative mortality. The results demonstrated that mortality was not higher than that for open procedures except for hemi‐hepatectomy with biliary reconstruction. An online prospective registry system for LLR was established in 2015 to be transparent for patients who might potentially undergo treatment with this newly developed, technically demanding surgical procedure.

show abstract

“…Likewise, resection for hepatic metastases of neuroendocrine tumors, including pancreatic neuroendocrine tumors, is widely accepted with the objective of symptom control and improved longterm outcome [34]. However, in patients undergoing liver resection for non-colorectal, non-neuroendocrine liver metastases, patient selection seems to be even more critical than in colorectal liver metastasis or primary liver tumors [35]; however, the significance of surgery has not been satisfactorily elucidated, especially regarding longterm outcome. Thus, there are still controversies concerning the oncological value of liver surgery in these patients.…”

Section: Role Of Surgerymentioning

confidence: 99%

Oligometastatic Disease in Pancreatic Cancer - How to Proceed

Renz

Boeck²,

Roeder

et al. 2017

Visc Med

Self Cite

View full text Add to dashboard Cite

Background: Pancreatic cancer is a highly aggressive malignancy and will become the second leading cause of cancer-related death in the USA and also in Germany by 2030. Furthermore, the majority of patients with pancreatic ductal adenocarcinoma (PDAC) will present with distant metastases, limiting surgical management in this population as there is little evidence available to support surgical or ablative treatment options for advanced-stage disease. However, highly selected patients suffering from synchronous and metachronous oligometastatic PDAC may potentially benefit from a surgical resection with an acceptable morbidity. Methods: This review summarizes and discusses the current literature on the management of oligometastatic disease regarding PDAC, focusing on para-aortic lymph nodes as well as isolated hepatic and pulmonary metastases. Results and Conclusion: In order to further investigate the feasibility and efficacy of such an approach, a prospective multicenter trial, in which survival and quality of life after metastatic resection and systemic chemotherapy is evaluated, has to be initiated. Additionally, local and locoregional ablation techniques or stereotactic body radiation therapy as therapeutic options for isolated metastases in PDAC need further research in order to determine their significance and benefit.

show abstract

Liver Resection for Non-colorectal Non-neuroendocrine Metastases: Where Do We Stand Today Compared to Colorectal Cancer?

Cited by 33 publications

References 47 publications

Surgical treatment of liver metastases from kidney cancer: a systematic review

Surgical treatment of liver metastases from kidney cancer: a systematic review

Evolution and revolution of laparoscopic liver resection in Japan

Oligometastatic Disease in Pancreatic Cancer - How to Proceed

Contact Info

Product

Resources

About